Company Description
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
The company was incorporated in 2016 and is based in Emeryville, California.
| Country | United States |
| IPO Date | Apr 6, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 236 |
| CEO | Dr. Brian Charles Thomas Ph.D. |
Contact Details
Address: 5959 Horton Street Emeryville, United States | |
| Website | https://www.metagenomi.co |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US59102M1045 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian Charles Thomas Ph.D. | Co-Founder, Chief Executive Officer & Chairman of the Board |
| Dr. Jian Irish M.B.A., Ph.D. | President, Chief Operating Officer & Director |
| Pamela M. Wapnick M.B.A. | Chief Financial Officer |
| Dr. Alan Brooks Ph.D. | Senior Vice President of Preclinical |
| Dr. Christopher Brown | Head of Discovery |
| Dr. Joseph Knowles M.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Sarah B. Noonberg M.D., Ph.D. | Chief Medical Officer |
| Matthew L. Wein J.D. | Vice President of Corporate Legal, Compliance & Corporate Secretary |
| Simon Harnest M.Sc. | Chief Investment Officer & Senior Vice President of Investor Relations |